DOCSLIB.ORG

DRUGS USED in PREGNANCY (Part 1 of 2)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
DRUGS USED in PREGNANCY (Part 1 of 2) DRUGS USED IN PREGNANCY (Part 1 of 2) Allergic Disorders Dental Glucovance (glyburide/metformin HCl), Glumetza (metformin HCl), Glyburide , Category A Category A Glynase (glyburide), Glyset ( miglitol), • Doxylamine • None available Humalog (insulin lispro), Humalog Category B Category B Mix 50/50, 75/25 (in sulin lispro • Benadryl (diphenhydramine)–3 rd • Aphthasol (amlexanox), Fluoridex protamine/insulin lispro), Janumet t rimester, Chlor-Trimeton (sodium fluoride), Peridex (sitagliptin/metformin), Januvia ( chlorpheniramine), Cyproheptadine , ( chlorhexidine gluconate) ( sitagliptin), Levemir (insulin Gastrocrom ( cromolyn sodium), detemir), Lutrepulse (gonadorelin Dermatological Disorders Singulair ( montelukast), Xyzal acetate), Novolog (insulin aspart), ( levocetirizine), Zyrtec (cetirizine Category A Novolog Mix 70/30 (insulin aspart HCl) • None available protamine/insulin aspart), Parlodel - (bromocriptine), Precose (acarbose) Cardiovascular System Category B Riomet (metformin HCl), Saizen • Acticin (permethrin), Altabax Category A (somatropin), Sandostatin (octreotide ( retapamulin), Amevive (alefacept), acetate), Serostim (somatropin) • None available Azelex (azelaic acid), Bactroban Category B (mupirocin), Centany (mupirocin), Eye Disorders • Aggrastat (tirofiban), Angiomax Denavir (penciclovir), Cleocin T (clindamycin), Clindagel Category A (bivalirudin), Argatroban • None available ( argatroban), Arixtra (fondaparinux ( clindamycin), Clindets sodium), Betapace , Betapace AF (clindamycin), Elimite (permethrin), Category B (sotalol HCl), Colestid (colestipol), Enbrel ( etanercept), Evoclin • Alocril (nedocromil sodium), Alomide Cyklokapron (tranexamic acid), ( clindamycin), Finacea (azelaic (lodoxamide tromethamine), Demadex ( torsemide), Dobutamine , acid), Kerol Emulsion (urea), Lamisil Alphagan P (brimonidine tartrate), Edecrin (ethacrynic acid), ( terbinafine HCl), Lac-Hydrin CREAM Azasite (azithromycin), Crolom Fenoldopam , Flolan (epoprostenol), (ammonium l actate), Loprox ( cromolyn sodium), Emadine Fragmin (dalteparin sodium), (ciclopirox), Lotrimin ( clotrimazole), (emedastine), Opticrom (cromolyn Hydrodiuril (hydrochlorothiazide), Mentax (butenafine HCl), sodium), Propine (dipivefrin HCl), Imdur ( isosorbide mononitrate, Metrocream (metronidazole), Tobrex (tobramycin) Metrogel ( metronidazole), extended release), Indapamide , Gastrointestinal tract Innohep ( tinzaparin sodium), Metrolotion ( metronidazole), Naftin Inspra (eplerenone), Integrilin (naftifine HCl), Nix ( permethrin), Category A ( eptifibatide), Kinlytic (urokinase), Noritate ( metronidazole), Ovide • Doxylamine (malathion), Oxistat (oxiconazole Lidocaine , Lovenox ( enoxaparin Category B sodium), Microzide nitrate), Penlac (ciclopirox), Remicade ( infliximab), Silvadene • Aciphex (rabeprazole sodium), ( hydrochlorothiazide), Midamor Actigall (ursodiol), Alinia (amiloride HCl), Moduretic (amiloride (silver sulfadiazine), Solaraze (diclofenac sodium)–1 st & 2 nd ( nitazoxanide), Aloxi (palonosetron), HCl/hydrochlorothiazide), Antivert (meclizine), Anzemet Methyldopa , Monoket (isosorbide trimester, SSD , SSD AF (silver sulfadiazine)–early pregnancy, (d olasetron mesylate), Azulfidine mononitrate), Persantine (sulfasalazine), Bentyl (dicyclomine), ( dipyridamole), Pindolol , Plavix Zonalon (doxepin HCl), Zovirax (acyclovir) Canasa (mesalamine), Carafate (clopidogrel), Refludan ( lepirudin), (sucralfate), Colazal (balsalazide Remodulin (treprostinil sodium), Endocrine System sodium), Delzicol (mesalamine), Revatio (sildenafil citrate), Sectral Dramamine (dimenhydrinate), (acebutolol), Stimate ( desmopressin Category A Dulcolax (bisacodyl), Emend acetate), Tenex ( guanfacine), • Armour Thyroid (liothyronine/ (aprepitant), Granisetron , Humira Ticlopidine HCl , Welchol levothyroxine), Cytomel ( liothyronine (adalimumab), Imodium ( colesevelam HCl), Zaroxolyn sodium), Levothroid (levothyroxine (loperamide), Kristalose (lactulose), (metolazone) sodium), Levoxyl (levothyroxine Lialda (mesalamine), Lotronex Central Nervous System sodium), Synthroid (levothyroxine (alosetron), Nexium (esomeprazole), sodium), Thyrolar (liothyronine Nizatidine , Pentasa (mesalamine), Category A sodium/levothyroxine sodium), Pepcid (famotidine), Prevacid • Magnesium Sulfate Triostat (liothyronine), Unithroid (lansoprazole), Protonix ( levothyroxine sodium) Category B (pantoprazole), Reglan • Buspirone HCl , Clozaril (clozapine), Category B (metoclopramide), Remicade Cylert (pemoline), Exelon • DDAVP (desmopressin acetate), (infliximab), Robinul (rivastigmine), Fazaclo ( clozapine), Dostinex (cabergoline), Fortamet (glycopyrrolate), Rowasa Namenda (memantine HCl), Parlodel (metformin HCl), Genotropin (mesalamine), Tagamet (bromocriptine), Propofol , Razadyne (somatropin), Glucagen (glucagon), (cimetidine), Urso (ursodiol), (galantamine), Xyrem (sodium Glucagon (glucagon), Glucophage , Vancocin (vancomycin), Zantac oxybate) Glucophage XR (metformin HCl), (r anitidine), Zofran (ondansetron) Not an inclusive list. (continued) DRUGS USED IN PREGNANCY (Part 2 of 2) Immune System (emtricitabine/tenofovir disoproxil Metrogel-Vaginal (metronidazole), fumarate), Tyzeka (telbivudine), Prometrium (progesterone)–not Category A Unasyn (ampicillin sodium/ indicated for use during pregnancy; • None available sulbactam sodium), Valtrex Vandazole (metronidazole) Category B (valacyclovir), Veetids (penicillin V • Copaxone (glatiramer acetate), potassium), Velosef (Cephradine), Pain Management Gardasil (quadrivalent human Videx , Videx EC (didanosine), Category A papillomavirus) Viracept (Nelfinavir), Viread • None available (t enofovir disoproxil fumarate), Infectious Diseases Zinacef (cefuroxime), Zithromax Category B (azithromycin), Zmax (azyithromycin), • EMLA (lidocaine/prilocaine), Category A Lidoderm (lidocaine), Naropin • None available Zosyn (piperacillin/tazobactam), Zovirax (acyclovir) ( ropivacaine), Oxycontin ( oxycodone Category B HCl), Oxyfast ( oxycodone HCl), • Abelcet (amphotericin B lipid Musculoskeletal Disorders Synera ( lidocaine/tetracaine), complex), Ambisome (amphotericin B Tylenol ( acetaminophen), Xylocaine liposome), Amoxil (amoxicillin), Category A (lidocaine) Amphotec (amphotericin B • None available cholesteryl sulfate), Ancef Category B Poisoning & Drug Dependence ( cefazolin), Augmentin (amoxicillin/ • Amrix (cyclobenzaprine), Azulfidine Category A clavulanic acid), Azactam EN-tabs (sulfasalazine), • None available ( aztreonam), Bicillin CR (penicillin G Cyclobenzaprine , Enbrel benzathine/penicillin G procaine), (etanercept), Fexmid Category B Bicillin LA (penicillin G benzathine), ( cyclobenzaprine), Humira • Acetadote (acetylcysteine), Ceclor (cefaclor), Cedax ( adalimumab), Kineret (anakinra), Calcium Disodium Versenate ( ceftibuten), Cefdinir , Cefotetan , Remicade (infliximab) (edatate calcium disodium), Exjade (deferasirox), Narcan Cefizox (ceftizoxime sodium), Neoplasms Cefobid (cefoperazone sodium), (Naloxone), Revex (nalmefene HCl) Cefpodoxime Proxetil , Ceftin Category A Respiratory tract (cefuroxime), Cefzil (cefprozil), • None available Claforan (cefotaxime sodium), Category A Category B • None available Cleocin ( clindamycin), Cubicin • Mesnex (mesna) (daptomycin), Dispermox Category B (amoxicillin), Duricef (cefadroxil), Nutrition • Accolate (zafirlukast), Atrovent E.E.S. (erythromycin), Emtriva (ipratropium bromide), Brethine Category A (emtricitabine), EryC (erythromycin), (terbutaline sulfate), Dopram • Folic acid (Category C if exceed Eryped ( erythromycin), Ery-tab ( doxapram), Intal (cromolyn RDA), Magnesium Sulfate , (erythromycin), Famvir (famciclovir), sodium), Pulmicort (budesonide), Vitamin A (Category X if exceed Flagyl (metronidazole)–2 nd & 3 rd Pulmozyme (dornase alfa), RDA), Vitamin B (Category C if t rimesters, contraindicated 1 st 12 Rhinocort Aqua (budesonide), trimester for trichomoniasis; exceed RDA), Vitamin C (Category C Singulair (montelukiast), Tilade Fortaz (ceftazidime), Furadantin if exceed RDA), Vitamin D (Category (nedocromil sodium), Xolair ( nitrofurantoin), Fuzeon (enfuvirtide), D if exceed RDA), Vitamin E ( omalizumab) Geocillin (carbenicillin), Invanz (Category C if exceed RDA), (ertapenem), Invirase (saquinavir), Pantothenic acid (Category C if Urogenital System Keflex (cephalexin), Lamisil exceed RDA), Pyridoxine (Category C if exceed RDA), Riboflavin (Category Category A ( terbinafine), Macrobid • None available ( nitrofurantoin)–1 st & 2 nd trimesters, C if exceed RDA), Thiamine Macrodantin ( nitrofurantoin)–1st & (Category C if exceed RDA) Category B 2 nd trimesters, Maxipime Category B • DDAVP (desmopressin acetate), (cefepime), Mefoxin (cefoxitin • Carnitor (levocarnitine), Tenuate Ditropan, Ditropan XL (oxybutynin sodium), Merrem (meropenem), (diethylpropion) chloride), Elmiron (pentosan Monurol (fosfomycin), Norvir polysulfate sodium), Hectorol (ritonavir), PCE (erythromycin), Ob/Gyn ( doxercalciferol), Oxytrol Principen (ampicillin), Raniclor (oxybutynin), Pyridium Category A (phenazopyridine) (cefaclor), Reyataz (atazanavir), • Nystatin vaginal (nystatin) Rocephin (ceftriaxone sodium), Selzentry (maraviroc), Spectracef Category B (cefditoren), Suprax (cefixime), • Cleocin Vaginal (clindamcyin), Clindesse (clindamycin), Flagyl Synercid (quinupristin/dalfopristin), nd rd Timentin (ticarcillin/ clavulanate), (metronidazole)–2 & 3 trimester, Trimox (amoxicillin), Truvada Gyne-Lotrimin (clotrimazole), Not an inclusive list. (Rev. 6/2013) .
Load more

Recommended publications
  • Package Leaflet: Information for the User Innohep® 10,000 IU/Ml Solution for Injection Tinzaparin Sodium
    Package leaflet: Information for the user innohep® 10,000 IU/ml solution for injection tinzaparin sodium Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. • In this leaflet innohep 10,000 IU/ml will be called innohep. What is in this leaflet 1. What innohep® is and what it is used for 2. What you need to know before you use innohep® 3. How to use innohep® 4. Possible side effects 5. How to store innohep® 6. Contents of the pack and other information 1. What innohep® is and what it is used for innohep is a type of heparin – a low molecular weight heparin – and belongs to a group of medicines called anticoagulants; these medicines affect how your blood clots. innohep prevents clotting, allowing normal blood flow through the arteries and veins. innohep is used to: Prevent blood clots in adults before and after an operation. Prevent blood clots in adults who have an increased risk of blood clots e.g. due to an acute illness with limited mobility. Prevent blood clots being formed in haemodialysis equipment in patients undergoing haemodialysis or haemofiltration.
    [Show full text]
  • SPECIALTY MEDICATIONS Available Through Accredo Health Group, Inc., Medco’S Specialty Pharmacy Call Toll-Free (800) 803-2523, 8:00 A.M
    SPECIALTY MEDICATIONS available through Accredo Health Group, Inc., Medco’s specialty pharmacy Call toll-free (800) 803-2523, 8:00 a.m. to 8:00 p.m., eastern time, Monday through Friday, to confirm that your medication is covered. Effective as of July 1, 2011 Abraxane® (paclitaxel protein-bound particles) Berinert® (C 1 esterase inhibitor [human])* (PA) (QD) Actemra ™ (tocilizumab) (PA) Betaseron® (interferon beta-1b) (PA) Actimmune® (interferon gamma-1b) (PA) Botox® (botulinum toxin type A) (PA) Adagen® (pegademase bovine) Carbaglu ™ (carglumic acid) Adcirca® (tadalafil) (ST) (QD) Carimune® NF (immune globulin intravenous [human]) (PA) Advate® (antihemophilic factor [recombinant]) (CPA) Cerezyme® (imiglucerase) (CPA) (ST) Afinitor® (everolimus) (PA) (QD) Cimzia® (certolizumab pegol) (ST) Aldurazyme® (laronidase) (CPA) Copaxone® (glatiramer acetate) (PA) Alphanate® (antihemophilic factor [human]) (CPA) Copegus® (ribavirin) (ST) AlphaNine® SD (coagulation factor IX [human]) (CPA) Corifact® (factor XIII [human]) (CPA) Amevive® (alefacept) (PA) Cystadane® (betaine) Ampyra ™ (dalfampridine) (PA) CytoGam® (cytomegalovirus immune globulin Apokyn® (apomorphine hydrochloride) (PA) (QD) intravenous [human])* (CPA) Aralast® (alpha[1]-proteinase inhibitor [human]) Cytovene® IV (ganciclovir sodium)* Aranesp® (darbepoetin alfa) (PA) Dacogen® (decitabine) Arcalyst® (rilonacept) (PA) (QD) Dysport® (abobotulinumtoxinA) (PA) Arixtra® (fondaparinux sodium)* Egrifta ™ (tesamorelin) (PA) Arranon® (nelarabine) Elaprase® (idursulfase) (CPA) Arzerra® (ofatumumab)
    [Show full text]
  • Hemosil ® Liquid Anti-Xa
    H E M O S I L® LIQUID ANTI-XA Measuring heparin and apixaban: Simple, fast, 24/7 • Liquid formulation, ready-to-use • One-stage, chromogenic anti-Xa assay • Universal calibration for unfractionated heparin (UFH) and low molecular weight heparin (LMWH) • Drug specific calibrators and controls for measurement of apixaban Measuring heparin and apixaban Unfractionated and low molecular weight heparin Heparin is a highly sulfated polysaccharide Laboratory monitoring is extremely important to characterized by a wide molecular weight range and assess the appropriate level of anticoagulation in potent anticoagulant activity. It exists either as UFH patients receiving UFH. Anti-Xa is recommended for or as depolymerized LMWH. UFH and LMWH have measuring both UFH and LMWH. a rapid anticoagulant effect and are used in the prevention and treatment of venous thrombosis and Anti-Xa testing for measuring UFH helps improve acute coronary syndrome. quality of care and patient experience while reducing costs, when compared with APTT testing.1 UFH and LMWH anticoagulant activity occurs when The advantages include: a complex with antithrombin (AT) is formed, • Higher precision potentiating its anticoagulant activity up to • Lower levels of discordant results1,2,4 1,000-fold, which inactivates both thrombin (FIIa) • Faster time to achieve therapeutic levels1,3,4 and Factor Xa (FXa). UFH acts through both FIIa 1,3,4,5 and FXa inhibition, while LMWH is a more efficient • Fewer tests and dosage changes catalyst for FXa inhibition. Direct Xa inhibitors Anticoagulation for patients with venous DOACs do not require routine monitoring. However, thromboembolism (VTE) previously included there are specific instances when an understanding heparin, heparin derivatives and/or oral vitamin K of the DOAC concentration in a patient sample may antagonists.
    [Show full text]
  • Saizen Prior Authorization Request Form (Page 1 of 4) DO NOT COPY for FUTURE USE
    OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations. Visit go.covermymeds.com/OptumRx to begin using this free service. Please note: All information below is required to process this request. Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific ® Saizen Prior Authorization Request Form (Page 1 of 4) DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED Member Information (required) Provider Information (required) Member Name: Provider Name: Insurance ID#: NPI#: Specialty: Date of Birth: Office Phone: Street Address: Office Fax: City: State: Zip: Office Street Address: Phone: City: State: Zip: Medication Information (required) Medication Name: Strength: Dosage Form: Check if requesting brand Directions for Use: Check if request is for continuation of therapy Clinical Information (required) Select the diagnosis below: Pediatric growth hormone deficiency Growth hormone deficiency in adults Growth hormone deficiency in transition phase adolescents Isolated growth hormone deficiency in adults Pediatric growth failure associated with chronic renal insufficiency Prader-Willi syndrome Short-stature homeobox (SHOX) gene deficiency Small for gestational age (SGA) Turner syndrome or Noonan syndrome Other diagnosis: _________________________________________ ICD-10 Code(s): ___________________________________ Clinical Information: Select if the requested medication is prescribed by or in consultation with one of the following
    [Show full text]
  • TITLE: Tinzaparin Versus Dalteparin Or Enoxaparin for the Treatment of Venous Thromboembolism in Adults: Safety and Guidelines
    TITLE: Tinzaparin versus Dalteparin or Enoxaparin for the Treatment of Venous Thromboembolism in Adults: Safety and Guidelines DATE: 12 March 2013 RESEARCH QUESTION 1. What is the clinical evidence for the safety of tinzaparin versus dalteparin or enoxaparin for the treatment of venous thromboembolism in adults with a glomerular filtration rate (eGFR) less than 30 ml/min? 2. What is the clinical evidence for the safety of tinzaparin versus dalteparin or enoxaparin for the treatment of venous thromboembolism in adults who require dialysis? 3. What are the evidence-based guidelines for the use of tinzaparin for adults with venous thromboembolism and a glomerular filtration rate less than 30 mL/min or adults who require dialysis? KEY MESSAGE Two meta-analyses, one randomized controlled trial, and one non-randomized study were identified regarding the safety of tinzaparin versus dalteparin or enoxaparin for the treatment of venous thromboembolism. No evidence-based guidelines were identified. METHODS A limited literature search was conducted on key resources including Pubmed, The Cochrane Library (2013, Issue 2), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No methodological filters were applied. Where possible, retrieval was limited to the human population. The search was also limited to documents published between January 1, 2003 and March 1, 2013. Internet links were provided, where available. Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews.
    [Show full text]
  • September 2017 ~ Resource #330909
    −This Clinical Resource gives subscribers additional insight related to the Recommendations published in− September 2017 ~ Resource #330909 Medications Stored in the Refrigerator (Information below comes from current U.S. and Canadian product labeling and is current as of date of publication) Proper medication storage is important to ensure medication shelf life until the manufacturer expiration date and to reduce waste. Many meds are recommended to be stored at controlled-room temperature. However, several meds require storage in the refrigerator or freezer to ensure stability. See our toolbox, Medication Storage: Maintaining the Cold Chain, for helpful storage tips and other resources. Though most meds requiring storage at temperatures colder than room temperature should be stored in the refrigerator, expect to see a few meds require storage in the freezer. Some examples of medications requiring frozen storage conditions include: anthrax immune globulin (Anthrasil [U.S. only]), carmustine wafer (Gliadel [U.S. only]), cholera (live) vaccine (Vaxchora), dinoprostone vaginal insert (Cervidil), dinoprostone vaginal suppository (Prostin E2 [U.S.]), varicella vaccine (Varivax [U.S.]; Varivax III [Canada] can be stored in the refrigerator or freezer), zoster vaccine (Zostavax [U.S.]; Zostavax II [Canada] can be stored in the refrigerator or freezer). Use the list below to help identify medications requiring refrigerator storage and become familiar with acceptable temperature excursions from recommended storage conditions. Abbreviations: RT = room temperature Abaloparatide (Tymlos [U.S.]) Aflibercept (Eylea) Amphotericin B (Abelcet, Fungizone) • Once open, may store at RT (68°F to 77°F • May store at RT (77°F [25°C]) for up to Anakinra (Kineret) [20°C to 25°C]) for up to 30 days.
    [Show full text]
  • ANONYMOUS V MERCK SERONO Conduct of Representative
    CASE AUTH/2591/3/13 ANONYMOUS v MERCK SERONO Conduct of representative An anonymous, non-contactable complainant, An anonymous, non-contactable complainant, complained about the conduct of an un-named complained about the conduct of an un-named representative from Merck Serono who had representative from Merck Serono. requested a monthly visit throughout 2013. The complainant stated that he/she felt harassed as COMPLAINT such frequent meetings were unnecessary. The complainant was informed that these visits were The complainant was concerned about a meeting required to meet an instruction to have meetings that he/she had had with a Merck Serono with seven health professionals each day. representative. The complainant alleged that the representative had requested that he/she plan a The complainant noted that before this episode, monthly visit with him/her throughout 2013. The he/she had always found the representative to be complainant stated that he/she felt harassed by this very professional and an asset to the company. The request as such frequent meetings were completely complainant considered that the representatives unnecessary. When the complainant asked why the were being forced to behave in this way by representative wanted to plan so many meetings in unrealistic expectations from their managers. advance he/she was informed that these visits were required to meet an instruction to have meetings The detailed response from Merck Serono is given with seven health professionals each day. below. The complainant noted that before this episode, he/ The Panel noted that Merck Serono’s instructions to she had always found this representative to be very its representatives referred to a number of different professional and an asset to his/her company.
    [Show full text]
  • What You Need to Know About Deep Vein Thrombosis (DVT)
    What You Need to Know About Deep Vein Thrombosis What is a Deep Vein Thrombosis? A deep vein thrombosis (DVT) is a blood clot that forms in the veins in the body (usually in the leg or pelvis). What causes a Deep Vein Thrombosis? Deep vein thrombosis (DVT) sometimes occurs for no apparent reason. However, certain factors can increase the chance of developing a DVT: • Inactivity • Hospital stays and surgery • Damage to your blood vessel from an injury or trauma • Medical and genetic conditions • Pregnancy • Taking estrogen-based medicine such as hormonal birth control or hormone replacement therapy • Overweight or obese • Family history of DVT • Older age What are the symptoms of DVT? Only about half of the people who have a DVT have signs and symptoms. These signs and symptoms of a deep vein clot include: • Pain or tenderness, often starting in the calf. • Swelling, including the ankle & foot. • Warmth and redness of the area or a noticeable discoloration Vascular Surgery -1- How is a DVT diagnosed? Your doctor will ask you questions about your symptoms and if your symptoms suggest that a blood clot is likely, you could have one or all of the following tests: • Blood test for a D-dimer: this test measures the level of a compound released when blood clots are dissolving. A high level may mean you have Deep Vein Thrombosis (DVT). • Imaging studies: o Ultrasound – This is the most common test for diagnosing deep vein blood clots. This test uses sound waves to create pictures of blood flowing through the arteries and veins in the affected leg.
    [Show full text]
  • GROWTH HORMONE (Adult Therapy) Genotropin, Humatrope, Norditropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Sogroya*, Zomacton
    GROWTH HORMONE (Adult therapy) Genotropin, Humatrope, Norditropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Sogroya*, Zomacton Bolded medications are the preferred products *This medication is included in this policy but is not available in the market as of yet RATIONALE FOR INCLUSION IN PA PROGRAM Background Growth hormone deficiency (GHD) in adulthood, associated with hypothalamic-pituitary dysfunction is now widely accepted as a distinct clinical syndrome, and is linked to a substantial number of significant co-morbidities, many of which can be ameliorated with growth hormone replacement therapy (1). The FDA has approved growth hormone replacement for use in adult patients with growth hormone deficiency. Approved indications are for the treatment of adults with either adult onset or childhood onset GHD. With the exception of idiopathic adult onset GHD, GHD should be confirmed as due to pituitary disease from known causes, including pituitary tumor, pituitary surgical damage, hypothalamic disease, irradiation, trauma, or reconfirmed childhood GHD. Growth hormone should only be prescribed to patients with clinical features suggestive of adult GHD and biochemically proven evidence of adult GHD (1-9). Regulatory Status FDA approved indications: Human growth hormone is indicated for treatment of adult patients with either childhood-onset or adult-onset GH deficiency (2-9). The laboratory diagnosis of GHD in adults is determined by dynamic endocrine testing. Because growth hormone has a short half-life in blood growth hormone levels frequently are undetectable in blood samples obtained at random from normal subjects. For this reason, a stimulation test is needed to confirm the diagnosis. American Association of Clinical Endocrinologists (AACE) does not recommend growth hormone stimulation testing in patients with three or more pituitary hormone deficiencies and low IGF1 (2-9).
    [Show full text]
  • Specialty Guideline Management
    Reference number(s) 1741-A SPECIALTY GUIDELINE MANAGEMENT GENOTROPIN (somatropin) HUMATROPE (somatropin) NORDITROPIN (somatropin) NUTROPIN AQ (somatropin) OMNITROPE (somatropin) SAIZEN (somatropin) ZOMACTON (somatropin) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no contraindications or exclusions to the prescribed therapy. A. FDA-Approved Indications 1. Pediatric patients with growth failure due to any of the following: a. Growth hormone (GH) deficiency b. Turner syndrome c. Noonan syndrome d. Small for gestational age (SGA) e. Prader-Willi syndrome f. Chronic kidney disease (CKD) g. Short stature homeobox-containing gene (SHOX) deficiency h. Idiopathic short stature (ISS)* 2. Adults with childhood-onset or adult-onset GH deficiency * ISS may not be covered by some plans B. Compendial Uses 1. Human immunodeficiency virus (HIV)-associated wasting/cachexia 2. Short bowel syndrome (SBS) 3. Growth failure associated with any of the following: a. Cerebral palsy b. Congenital adrenal hyperplasia c. Cystic fibrosis d. Russell-Silver syndrome All other indications are considered experimental/investigational and not medically necessary. II. REQUIRED DOCUMENTATION The following information is necessary to initiate the prior authorization review for both initial and continuation of therapy requests (where applicable): A. Medical records supporting the diagnosis of neonatal GH deficiency Growth Hormone With ISS 1741-A SGM P2021.docx © 2021 CVS Caremark. All rights reserved. This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.
    [Show full text]
  • Medicines/Pharmaceuticals of Animal Origin V3.0 November 2020
    Medicines/pharmaceuticals of animal origin V3.0 November 2020 Medicines/pharmaceuticals of animal origin - This guideline provides information for all clinical staff within Hospital and Health Services (HHS) on best practice for avoidance of issues related to animal products. Medicines/pharmaceuticals of animal origin - V3.0 November 2020 Published by the State of Queensland (Queensland Health), November 2020 This document is licensed under a Creative Commons Attribution 3.0 Australia licence. To view a copy of this licence, visit creativecommons.org/licenses/by/3.0/au © State of Queensland (Queensland Health) 2020 You are free to copy, communicate and adapt the work, as long as you attribute the State of Queensland (Queensland Health). For more information contact: Medication Services Queensland, Queensland Health, GPO Box 48, Brisbane QLD 4001, email [email protected] An electronic version of this document is available at https://www.health.qld.gov.au/__data/assets/pdf_file/0024/147507/qh-gdl-954.pdf Disclaimer: The content presented in this publication is distributed by the Queensland Government as an information source only. The State of Queensland makes no statements, representations or warranties about the accuracy, completeness or reliability of any information contained in this publication. The State of Queensland disclaims all responsibility and all liability (including without limitation for liability in negligence) for all expenses, losses, damages and costs you might incur as a result of the information being inaccurate
    [Show full text]
  • Innohep® Is and What It Is Used for • If You Have Kidney Problems
    Scale Get-up Material No Sent by e-maiL l 5. RBE 100% GB 066478-XX Subject Date Date 14/09/20 066478 INS 205 x 315 mm with 2 foils 27/05/20 066478-XX Colour Sign. Sign. SOP_000647, SOP_000962, SOP_000647, SOP_000962 Black OMA SOP_003993 and and SOP_008676 SOP_008676 Preparation Place of production Strength ® Packsize innohep syringe 20,000 IU/ml France Comments: Page 1 of 2 Font size: 9 pt Headings 10 pt Mock-up for reg. purpose IFR012-01 - 205 x 315 mm Page 4 of 4 Page 1 of 4 066478-XX Package leaflet: Information for the user syringe 20,000 IU/ml tinzaparin sodium Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. 066478 • If you have any further questions, ask your doctor, pharmacist or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. • In this leaflet innohep 20,000 IU/ml syringe will be called innohep. What is in this leaflet • If you have an artificial heart valve. 1. What innohep® is and what it is used for • If you have kidney problems. 2. What you need to know before you use innohep® • If you have asthma, as this medicine contains sodium 3.
    [Show full text]